STAGE IIB MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8
Clinical trials for STAGE IIB MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIB MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IIB MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for rare skin cancer
Disease control Recruiting nowThis study tests whether combining a light-based blood treatment (ECP) with a targeted antibody drug (mogamulizumab) can better control erythrodermic cutaneous T-cell lymphoma (CTCL), a rare skin cancer. About 34 adults with advanced CTCL will receive both treatments to see if th…
Matched conditions: STAGE IIB MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 01:48 UTC
-
New study aims to decode drug rash vs. disease worsening in rare skin cancers
Knowledge-focused Recruiting nowThis study looks at a common side effect—rash—from the drug mogamulizumab in people with mycosis fungoides or Sezary syndrome, two rare types of skin lymphoma. The rash can look like the cancer itself, leading doctors to stop treatment too early. Researchers will study 100 adults…
Matched conditions: STAGE IIB MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated May 15, 2026 11:54 UTC